The FDA is continuing to push ahead with its openFDA initiative, with this week's rollout of an application programming interface (API) for recall data coming a month after its adverse event system went live. And the regulator plans to maintain the pace throughout the rest of the summer.
Codexis strengthened its ties to small-molecule synthesis this week through a deal with GlaxoSmithKline. The agreement will see GSK pay $6 million upfront and more in milestones to license the platform.
Over the first few months of 2014, Novartis quietly began laying off workers, shedding an estimated 3,000 jobs in four months. Now BioSpace has provided details of where the ax has fallen and why, with development IT teams suffering heavy job losses.
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
When Illumina unveiled its HiSeq X Ten in January, the alignment between its capabilities and the needs of England's 100K Genome Project were clear. The project aims to sequence 100,000 genomes by 2017 for around $160 million, figures that only look achievable using the massive output and relatively low costs of the HiSeq X Ten. This week the tie-up became official.
After weeks of increasingly confident media speculation, Google has confirmed it is setting up an outpost of its venture capital wing in Europe. And with a brief to follow a similar strategy to the U.S. team that invested in Flatiron Health, DNAnexus and other biotech IT startups, the $100 million fund is a new source of capital for European life science innovators.
The drug is approved for treating--not preventing--hepatitis B, prompting FDA to call the advert misleading.
Although Numenta has made progress in creating apps that reproduce the brain, it thinks a fully functioning model is impossible without rethinking the underlying hardware.
PHT unveiled its electronic patient reported outcome app for Apple and Android devices last summer, but Google's platform has become its primary focus.
Two hundred eighty scientists have signed an open letter threatening to boycott Europe's Human Brain Project. The scientists have fundamental concerns about exactly what Europe is trying to achieve with its €1 billion ($1.4 billion) budget.
Over the past few years, Google has expanded into life sciences, with venture capital investments, the creation of Calico and development of "smart" contact lenses giving it multiple beachheads in the industry. But the search giant's co-founders have reservations about getting deep into healthcare, saying regulations make it a "painful" sector in which to work.
When the FDA laid out its strategic priorities for 2011 to 2015, the agency listed the modernization of its IT infrastructure as a primary objective. Since then, the FDA has seen another chief information officer pass through its revolving doors and faced criticism from the Government Accountability Office, but is still plugging away with the IT modernization agenda in its next strategic plan.
The potential to mine electronic medical records for insights into disease prevalence, drug adherence, patient safety and a host of other areas has attracted a who's who of Big Pharma, with the likes of GlaxoSmithKline, Johnson & Johnson and Pfizer all running programs. And now the FDA is pushing ahead with its plans by seeking access to a patient-level database.
When Y Combinator expanded into biotech, the startup incubator was effectively betting on the idea that IT has narrowed the gap between timelines and economics in life sciences and tech. The Wall Street Journal is the latest publication to profile the scene, picking out a batch of companies with similar models and ambitions to those featured by TechCrunch and FierceBiotechIT earlier this year.
If the Michigan-based company--which describes itself as "Match.com for clinical trials"--achieves its goal, it will have doubled the number of top-5 companies on its books.
The staff opposition that greeted news that the Scripps Research Institute is looking into a merger or other type of deal to ease its money worries has escalated over the past few weeks, culminating in an email to the chair of the board of trustees. In the email, Scripps' faculty leaders reportedly call for the removal of President Michael Marletta because they have lost confidence in his leadership.
Over the first 6 months of 2014, the FBI, cybersecurity monitors and others have criticized pharma's data defense practices. Yet now drugmakers--along with their peers in other industries--are being taken to task for focusing heavily on preventing information breaches instead of trying to tap databases to boost their businesses.
In the months since the United Kingdom slammed the breaks on its controversial patient data sharing scheme, officials have tried to hit upon a model that a now wary public will accept. And this looks set to result in a scaling back of the project's initial ambitions, with doctors calling for it to become an opt-in system and the group providing the technology admitting the program will start small.
Evangelists of 3-D printing tip the technology to reshape organ transplants, orthopedics and multiple other areas of medicines, with Johnson & Johnson among the companies trying to turn hype into reality. And now the National Institutes of Health has joined the sector, adding a 3-D model creation service to help drug researchers who lack computing skills.
While the debate over how to implement clinical trial data transparency laws rages in Europe, Big Pharma firms continue to roll out their own offerings, with Bristol-Myers Squibb the latest to show its hand. And the U.S. drugmaker has gone further than some of its peers by handing over decision-making powers to a third party and promising to publish full clinical study reports.